Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial

Lancet

Volumn 369, Issue 9573, 2007, Pages 1621-1626

  Chan, Francis Ka Leung ^a   Wong, Vincent Wai Sun ^a   Suen, Bing Yee ^a   Wu, Justin Che Yuen ^a   Ching, Jessica Yuet Ling ^a   Hung, Lawrence Cheung Tsui ^a   Hui, Aric Josun ^a   Leung, Vincent King Sun ^b   Lee, Vivian Wing Yan ^a   Lai, Larry Hin ^a   Wong, Grace Lai Hung ^a   Chow, Dorothy Kai Lai ^a   To, Ka Fa ^a   Leung, Wai Keung ^a   Chiu, Philip Wai Yan ^a   Lee, Yuk Tong ^a   Lau, James Yun Wong ^a   Chan, Henry Lik Yuen ^a   Ng, Enders Kwok Wai ^a   Sung, Joseph Jao Yiu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIHISTAMINIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESOMEPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; SUCRALFATE;

AGED; ANEMIA; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HELICOBACTER PYLORI; HIGH RISK PATIENT; HISTOLOGY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PEPTIC ULCER BLEEDING; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SKIN ALLERGY; STROKE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; UPPER GASTROINTESTINAL BLEEDING;

EID: 34248216918     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60749-1     Document Type: Article

References (29)

1. Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 18 suppl 26 (1991) 6-10
2. Langman M. Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?. Pharmacoepidemiol Drug Safety 10 (2001) 13-19
3. Garcia Rodriguez L., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
4. Chan F., Chung S., Suen B., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
5. Russell R. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgrad Med J 77 (2001) 82-88
6. Garcia Rodriguez L., and Ruigomez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology 10 (1999) 228-232
7. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
8. Schnitzer T., Burmester G., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
9. Singh G., Fort J., Goldstein J., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255-266
10. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
11. Schnitzer T. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 25 suppl 7 (2006) 22-29
12. Chan F., Hung L., Suen B., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
13. Chan F., Hung L., Suen B., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomised double-blind trial. Gastroenterology 127 (2004) 1038-1043
14. Lai K., Chu K., Hui W., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
15. Graham D. NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med 347 (2002) 2162-2164
16. Cryer B. COX-2 specific inhibitor or proton pump inhibitor plus traditional NSAID: Is either approach sufficient for patients at highest risk of NSAID-induced ulcers?. Gastroenterology 127 (2004) 1256-1258
17. Dubois R., Melmed G., Henning J., and Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19 (2004) 197-208
18. Chan F. Managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 563-573
19. Scheiman J., Yeomans N., Talley N., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
20. Lichtenstein D., Syngal S., and Wolfe M. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 38 (1995) 5-18
21. Matts J., and Lachin J. Properties of permuted-block randomization in clinical trials. Control Clin Trials 9 (1988) 327-344
22. Roumie C., Arbogast P., Mitchel Jr. E., and Griffin M. Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. J Gen Intern Med 20 (2005) 879-883
23. Zhao S., Burke T., Whelton A., von Allmen H., and Henderson S. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 8 suppl (2002) 414-427
24. Ashcroft D., Chapman S., Clark W., and Millson D. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. Ann Pharmacother 35 (2001) 829-834
25. Katz P., Castell D., Chen Y., Andersson T., and Sostek M. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomised, three-way crossover study. Aliment Pharmacol Ther 20 (2004) 399-406
26. Hammer J., and Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 19 (2004) 1105-1110
27. Lanas A., Baron J., Sandler R., et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 132 (2007) 490-497
28. Solomon S., McMurray J., Pfeffer M., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
29. Levesque L., Brophy J., and Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142 (2005) 481-489